Covered recipient · General Payments record
LAINIE MARTIN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$31,614.57
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $10,250.96 | 3 |
| Consulting Fee | $6,355.00 | 3 |
| Food and Beverage | $102.16 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genmab U.S., Inc. | $12,377.04 | 6 |
| ABBVIE INC. | $2,800.00 | 1 |
| Daiichi Sankyo Inc. | $1,455.00 | 1 |
| Acerta Pharma LLC | $76.08 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $2,800.00 | 04/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104973889 | CMS |
| AstraZeneca Pharmaceuticals LP | $76.08 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104634433 | CMS |
| Daiichi Sankyo Inc. | $1,455.00 | 03/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089452904 | CMS |
| Genmab U.S., Inc. | $9,198.03 | 10/01/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126828736 | CMS |
| Genmab U.S., Inc. | $7.82 | 10/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126828738 | CMS |
| Genmab U.S., Inc. | $18.26 | 10/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126828740 | CMS |
| Genmab U.S., Inc. | $490.00 | 10/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126828732 | CMS |
| Genmab U.S., Inc. | $562.93 | 10/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126828734 | CMS |
| Genmab U.S., Inc. | $2,100.00 | 12/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1126828730 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.